

# Bimal Bhindi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5405036/publications.pdf>

Version: 2024-02-01

89  
papers

1,974  
citations

257450

24  
h-index

254184

43  
g-index

89  
all docs

89  
docs citations

89  
times ranked

3301  
citing authors

#	ARTICLE	IF	CITATIONS
1	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, 2299-2305.	1.6	241
2	Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2019, 75, 111-128.	1.9	138
3	The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment. <i>European Urology</i> , 2018, 74, 489-497.	1.9	93
4	Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort. <i>European Urology</i> , 2015, 67, 64-70.	1.9	91
5	Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates. <i>Journal of Urology</i> , 2015, 193, 1519-1524.	0.4	90
6	Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 73, 834-844.	1.9	86
7	The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. <i>BJU International</i> , 2018, 121, 684-698.	2.5	79
8	Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. <i>European Urology</i> , 2017, 72, 660-664.	1.9	77
9	Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (<scp>ERSPC</scp>) and Prostate Cancer Prevention Trial (<scp>PCPT</scp>) risk calculators: independent validation and comparison in a contemporary European cohort. <i>BJU International</i> . 2016. 117, 401-408.	2.5	76
10	Predicting Renal Function Outcomes After Partial and Radical Nephrectomy. <i>European Urology</i> , 2019, 75, 766-772.	1.9	75
11	Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2018, 200, 528-534.	0.4	59
12	Obesity Is Associated with Risk of Progression for Low-risk Prostate Cancers Managed Expectantly. <i>European Urology</i> , 2014, 66, 841-848.	1.9	56
13	Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. <i>British Journal of Cancer</i> , 2016, 114, 207-212.	6.4	53
14	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 74, 309-321.	1.9	51
15	Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. <i>BJU International</i> , 2012, 110, 980-986.	2.5	45
16	Outcomes After Cryoablation Versus Partial Nephrectomy for Sporadic Renal Tumors in a Solitary Kidney: A Propensity Score Analysis. <i>European Urology</i> , 2018, 73, 254-259.	1.9	45
17	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 615-623.	1.9	44
18	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 343-350.	1.9	33

#	ARTICLE	IF	CITATIONS
19	The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 386.e7-386.e13.	1.6	31
20	Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. <i>Urology</i> , 2016, 93, 77-85.	1.0	31
21	The Association Between Vasectomy and Prostate Cancer. <i>JAMA Internal Medicine</i> , 2017, 177, 1273.	5.1	31
22	The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass. <i>Journal of Urology</i> , 2018, 200, 981-988.	0.4	30
23	The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e629-e636.	1.9	28
24	Are We Using the Best Tumor Size Cut-points for Renal Cell Carcinoma Staging?. <i>Urology</i> , 2017, 109, 121-126.	1.0	25
25	Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. <i>Journal of Urology</i> , 2017, 198, 1286-1294.	0.4	24
26	Obesity Is Associated With Larger Prostate Volume but not With Worse Urinary Symptoms: Analysis of a Large Multiethnic Cohort. <i>Urology</i> , 2014, 83, 81-87.	1.0	22
27	The Importance of Surgeon Characteristics on Impacting Oncologic Outcomes for Patients Undergoing Radical Cystectomy. <i>Journal of Urology</i> , 2014, 192, 714-720.	0.4	22
28	Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration. <i>Journal of Urology</i> , 2017, 198, 86-91.	0.4	20
29	Renal functional outcomes in patients undergoing percutaneous cryoablation or partial nephrectomy for a solitary renal mass. <i>BJU International</i> , 2017, 120, 544-549.	2.5	19
30	Electrochemical red-ox therapy of prostate cancer in nude mice. <i>Bioelectrochemistry</i> , 2015, 104, 1-9.	4.6	18
31	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. <i>Canadian Urological Association Journal</i> , 2016, 10, 25.	0.6	17
32	Comprehensive assessment of renal tumour complexity in a large percutaneous cryoablation cohort. <i>BJU International</i> , 2017, 119, 905-912.	2.5	14
33	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 603.e1-603.e7.	1.6	13
34	Synchronous nephron-sparing approaches for bilateral renal masses: perioperative and renal functional outcomes. <i>BJU International</i> , 2018, 122, 243-248.	2.5	12
35	Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort. <i>Canadian Urological Association Journal</i> , 2017, 11, 41.	0.6	11
36	Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2021, 205, 78-85.	0.4	11

#	ARTICLE	IF	CITATIONS
37	The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2019, 29, 507-512.	1.8	10
38	Canadian Urological Association guideline: Management of small renal masses – Full-text. <i>Canadian Urological Association Journal</i> , 2021, 16, E61-75.	0.6	10
39	Split Renal Function Is Fundamentally Important for Predicting Functional Recovery After Radical Nephrectomy. <i>European Urology Open Science</i> , 2022, 40, 112-116.	0.4	10
40	Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 836.e19-836.e27.	1.6	9
41	External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC. <i>Journal of Urology</i> , 2016, 196, 1402-1407.	0.4	8
42	Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version. <i>Canadian Urological Association Journal</i> , 2021, 15, 230-9.	0.6	8
43	Statin use and time to progression in men on active surveillance for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 509-515.	3.9	7
44	&lt;p&gt;Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 10043-10050.	1.9	7
45	Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, E424-E460.	0.6	7
46	The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. <i>Canadian Urological Association Journal</i> , 2016, 10, 424.	0.6	6
47	Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2018, 12, 203-10.	0.6	6
48	Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018, 74, 534-535.	1.9	6
49	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer. <i>Canadian Urological Association Journal</i> , 2019, 13, 377-383.	0.6	6
50	Systematic review and meta-analysis of trials evaluating the role of adjuvant radiation after radical prostatectomy for prostate cancer: Implications for early salvage. <i>Canadian Urological Association Journal</i> , 2020, 14, 330-336.	0.6	6
51	Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach. <i>Cancer Causes and Control</i> , 2021, 32, 675-680.	1.8	6
52	Metabolic syndrome and diabetes for the urologist. <i>Canadian Urological Association Journal</i> , 2014, 8, 159.	0.6	5
53	Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e1-166.e8.	1.6	5
54	Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin. <i>Urology</i> , 2017, 109, 145-152.	1.0	4

#	ARTICLE	IF	CITATIONS
55	Re: Robotic versus Open Level I-II Inferior Vena Cava Thrombectomy: A Matched Group Comparative Analysis. <i>Journal of Urology</i> , 2018, 199, 1351-1352.	0.4	3
56	Examining the association between adiposity and biochemical recurrence after radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2018, 12, E331-7.	0.6	3
57	Timing and distribution of early renal cell carcinoma recurrences stratified by pathological nodal status in M0 patients at the time of nephrectomy. <i>International Journal of Urology</i> , 2020, 27, 618-622.	1.0	3
58	The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. <i>Urology</i> , 2014, 84, 1073-1080.	1.0	2
59	Reply from Authors re: Andrea Gallina, Alessandro Nini, Francesco Montorsi, Alberto Briganti. Metabolic Syndrome as a Marker for Prostate Cancer: Still a Work in Progress. <i>Eur Urol</i> 2015;67:71-72. <i>European Urology</i> , 2015, 67, 72-73.	1.9	2
60	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 604.e17-604.e24.	1.6	2
61	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , 2018, 200, 1056-1061.	0.4	2
62	Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 135.e1-135.e8.	1.6	2
63	The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 499.e15-499.e22.	1.6	2
64	Utilization and outcomes of metastasectomy for patients with metastatic urothelial cancer: An analysis of the national cancer database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 61.e21-61.e28.	1.6	2
65	The Comparative Outcomes of Radical Prostatectomy versus Radiotherapy for Non-metastatic Prostate Cancer: A Longitudinal, Population-Based Analysis. <i>Journal of Urology</i> , 2020, , 101097JU00000000000000805.	0.4	2
66	Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, 131-131.	1.6	2
67	Ultrasound Correlates Highly With Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort. <i>Urology</i> , 2022, , .	1.0	2
68	A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System. <i>Journal of Urology</i> , 2022, 208, 804-812.	0.4	2
69	Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes. <i>World Journal of Urology</i> , 2017, 35, 1879-1884.	2.2	1
70	Selecting patients for prostate cancer treatment: the role of comorbidity. <i>BJU International</i> , 2018, 121, 164-165.	2.5	1
71	Adjuvant Versus Salvage Radiotherapy Following Radical Prostatectomy: Meta-analysis of the Effect of Comparator Salvage Approach on Study Conclusions. <i>European Urology</i> , 2020, 77, 395-396.	1.9	1
72	Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. <i>Canadian Urological Association Journal</i> , 2020, 15, 132-137.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Are We Moving Closer to Accurate Restaging after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer?. <i>European Urology</i> , 2021, 79, 372-373.	1.9	1
74	Canadian Urological Association guideline: Management of small renal masses – Summary of recommendations. <i>Canadian Urological Association Journal</i> , 2021, 16, 24-5.	0.6	1
75	Reply. <i>Urology</i> , 2014, 84, 1080.	1.0	0
76	Author Reply. <i>Urology</i> , 2016, 93, 85.	1.0	0
77	Editorial Comment. <i>Journal of Urology</i> , 2017, 198, 1052-1053.	0.4	0
78	Author Reply. <i>Urology</i> , 2017, 109, 152.	1.0	0
79	Editorial Comment. <i>Journal of Urology</i> , 2018, 200, 125-125.	0.4	0
80	Reply to Georgios Papadopoulos, Charalampos Fragkoulis, and Konstantinos Ntoumas – Letter to the Editor re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. <i>Eur Urol</i> 2017;72:660–4. <i>European Urology</i> , 2018, 73, e53.	1.9	0
81	Reply to Giulia I. Lane and Badrinath Konety's Letter to the Editor re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. <i>Eur Urol</i> 2017;72:660–4. <i>European Urology</i> , 2018, 73, e70-e71.	1.9	0
82	Survival outcomes for patients with surgically induced end-stage renal disease. <i>Canadian Urological Association Journal</i> , 2019, 14, E65-E73.	0.6	0
83	Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. <i>Eur Urol</i> 2019;75:766–72. Partial Nephrectomy: –Geocentrism– of the 21st century in the Church of Urology?. <i>European Urology</i> , 2019, 76, e67-e68.	1.9	0
84	Approach to the Management of Large and Advanced Renal Tumors. , 2019, , 139-165.		0
85	115: Local Prostate Radiotherapy in Patients with Metastatic Prostate Cancer and Symptomatic Local Events. <i>Radiotherapy and Oncology</i> , 2020, 150, S50-S51.	0.6	0
86	Reply By Authors. <i>Journal of Urology</i> , 2021, 205, 84-85.	0.4	0
87	Local salvage ablation therapy after radiation therapy for prostate cancer – are we there yet?. <i>Canadian Urological Association Journal</i> , 2020, 15, 130-1.	0.6	0
88	Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2021, 5, 129-135.	0.4	0
89	Editorial Comment. <i>Journal of Urology</i> , 2021, , 101097JU000000000000223001.	0.4	0